SCHEMBL1335600

SCHEMBL1335600

O=C(Nc1n[nH]c2ccc(OCc3cc(F)cc(F)c3)cc12)c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 6/20 0.50
FLT3 P36888 5/20 0.49
AURKA O14965 1/20 0.48
INSR P06213 1/20 0.48
IGF1R P08069 1/20 0.48
AURKB Q96GD4 1/20 0.48
ALK Q9UM73 1/20 0.48
CDK2 P24941 2/20 0.48
KIT P10721 3/20 0.45
NTRK3 Q16288 1/20 0.44
NTRK2 Q16620 1/20 0.44
CNR2 P34972 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
MAPT P10636 2/20 0.43
POLB P06746 1/20 0.43
THRB P10828 1/20 0.43
MCL1 Q07820 1/20 0.43
CTDSP1 Q9GZU7 1/20 0.43
CDK7 P50613 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1334911 0.90 MEN1 (0.55) NTRK1FLT3CDK2NTRK3NTRK2
SCHEMBL1336402 0.87 NTRK1 (0.53) NTRK1FLT3AURKAINSRIGF1R
SCHEMBL1336232 0.87 NTRK1 (0.65) NTRK1FLT3AURKAINSRIGF1R
SCHEMBL2482316 0.87 FLT3 (0.58) NTRK1FLT3AURKAINSRIGF1R
SCHEMBL1336528 0.86 NTRK1 (0.52) NTRK1FLT3AURKAINSRIGF1R
SCHEMBL18030719 0.84 FLT3 (0.45) NTRK1FLT3AURKAINSRIGF1R
SCHEMBL1334988 0.81 NTRK1 (0.53) NTRK1FLT3AURKAINSRIGF1R
SCHEMBL1336312 0.81 ULK1 (0.53) NTRK1FLT3AURKAINSRIGF1R
SCHEMBL1335582 0.80 NTRK1 (0.79) NTRK1FLT3AURKAINSRIGF1R
SCHEMBL1336217 0.80 FLT3 (0.49) NTRK1FLT3AURKAINSRIGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2373626-B1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2016-08-24 EP claimed
US-8354399-B2 Substituted indazole derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-01-15 US claimed
US-20110281843-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-11-17 US claimed
EP-2373626-B1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2016-08-24 EP disclosed
US-8354399-B2 Substituted indazole derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-01-15 US disclosed
US-20110281843-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-11-17 US disclosed
EP-2373626-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2011-10-12 EP disclosed
WO-2010069966-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-06-24 WO disclosed
WO-2010069966-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281843-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS MAP3K19, MAP3K3, MAP3K5 NTRK1 1510/4885FLT3 241/4885AURKA 289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.